ArticleFrontiers in neurology2025
Systemic endothelial glycocalyx shedding mediates vascular hyperpermeability after traumatic brain injury.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring and Targeted Regulation of Oxygen Metabolism in Pediatric Sepsis: Current Paradigms and Future Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In traumatic brain injury (TBI), the primary insult initiates a secondary cascade that exacerbates neuronal injury. Blood-brain barrier (BBB) dysfunction plays a central role in this process, leading to vascular leakage and vasogenic edema. Recent evidence suggests that the endothelial glycocalyx (eGC) is an essential structural component of the BBB. This study aimed to determine whether systemic eGC shedding after TBI contributes to vascular hyperpermeability and cerebral edema. Methods: We enrolled patients within 24 h of TBI. Blood and urine samples were collected to measure biomarkers of eGC shedding [syndecan-1 (SDC-1), soluble CD44 (CD44s), hyaluronan (HA), sulfated glycosaminoglycans (GAGs)], of endothelial cell damage [thrombomodulin (sTM)], of inflammation [interleukin-6 (IL-6)], and of vascular permeability [microalbuminuria]. Neuron-specific enolase (NSE) was measured as a surrogate marker of neuronal injury and BBB disruption. eGC thickness was estimated via sublingual microcirculation capillaroscopy using the perfused boundary region (PBR)-an inverse parameter of eGC thickness. Cranial computed tomography (CT) was used to assess signs of cerebral edema. A modified Rankin Scale (mRS) score ≥4 at 3 months was considered a poor neurological outcome. Results: We enrolled 55 TBI patients, and 20 healthy individuals served as controls. Compared with controls, TBI patients had significantly higher SDC-1, CD44s, GAGs, sTM, IL-6, NSE, and microalbuminuria levels, as well as higher adjusted PBR values. The levels of SDC-1, CD44s, sTM, IL-6, and microalbuminuria showed a statistically significant correlation with NSE levels. Additionally, a significant positive correlation was observed between microalbuminuria levels and adjusted PBR. Microalbuminuria was higher in those with cistern compression on CT and in those with poor neurological outcomes. Conclusion: Systemic eGC shedding appears to be an early and central pathophysiological event after TBI, contributing to systemic vascular hyperpermeability and thereby to the development of cerebral edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.